Pilbara Minerals (OTC:PILBF) Stock, Quote.Headers.trade-ideas

Pilbara Minerals Ltd is an industrial metals and materials company. The business is engaged in the exploration, development, and operation of the Pilgangoora Project. Pilbara Minerals has one business segment, Mining, that is engaged in mineral exploration, evaluation, and development of various mineral resources. The company generates the vast majority of its revenue in Australia. The company's primary property is the Pilgangoora Lithium-Tantalum Project in the Pilbara region of Western Australia.

Large Cap

Latin America

Mid Cap

News

Penny Stocks

Small Cap

Management

Markets

Analyst Ratings

Trading Ideas

ATLX

MITSF

PILBF

Lithium Co. Hits Permitting Milestone for Brazil Lithium Project

Government

Regulations

Price Target

Legal

LTHCF

Source: Streetwise Reports 09/20/2024

In Brazil&#39;s emerging lithium sector, a US$370 million acquisition of a local company has other junior explorers the wondering if they could be next.

Acquisition Has Other Brazil Lithium Cos. Wondering Who&#39;s Next

Advertising,Banner,Catl,Contemporary,Amperex,Technology,Limited,Electric,Vehicle,Battery

Commodities

CATL Halts Key Lithium Mine, Supply Squeeze Drive Analysts Predictions

PILBARA MINERALS LTD ORD by PILBARA MINERALS LTD

Pilbara Minerals Ltd

Rosenblatt analyst Blair Abernethy maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and maintains $635 price target.

SNPS

Rosenblatt Maintains Buy on Synopsys, Maintains $635 Price Target

Earnings

Guidance

General

CHWY

Chewy Expects 2024 Sales Of $11.79B-$11.81B Vs. Consensus Of $11.878B, With Adjusted EBITDA Margin Of 4.6%-4.8%

Keybanc analyst Sophie Karp upgrades Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) from Sector Weight to Overweight and maintains the price target from $101 to $101.

Upgrades

Keybanc Upgrades Pinnacle West Capital to Overweight, Maintains Price Target to $101

Chewy Expects Q4 2024 Sales Of $3.18B-$3.20B Vs. Consensus Of $3.174B

Rosenblatt analyst Hans Mosesmann maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and raises the price target from $120 to $140.

MRVL

Rosenblatt Maintains Buy on Marvell Tech, Raises Price Target to $140

Keybanc analyst Sophie Karp downgrades Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) from Overweight to Sector Weight.

Downgrades

Keybanc Downgrades Entergy to Sector Weight

ALTR

Altair Will Work Together With Auburn University's Samuel Ginn College Of Engineering On A $1.25M FWERX Phase II STTR Contract

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Entered Into A Strategic Collaboration With Westchester Medical Center In Valhalla, New York

Benchmark analyst Cody Acree reiterates Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and raises the price target from $115 to $135.

Reiteration

Benchmark Reiterates Buy on Marvell Tech, Raises Price Target to $135

TLRY

Hop Valley Brewing And Subsidiary Of Tilray Brands, Is Excited To Announce Its New Partnership With The Portland Trail Blazers And The Opening Of The Hop Valley Brewing Hop Box Bar Inside Moda Center

Keybanc analyst Sophie Karp downgrades DTE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>) from Overweight to Sector Weight.

Keybanc Downgrades DTE Energy to Sector Weight

Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.08 by 150 percent. The company reported quarterly sales of $2.88 billion which missed the analyst consensus estimate of $2.90 billion by 0.88 percent. This is a 5.02 percent increase over sales of $2.74 billion the same period last year.

Chewy Q3 2024 Adj EPS $0.20 Beats $0.08 Estimate, Sales $2.88B Miss $2.90B Estimate

D. Boral Capital analyst Jason Kolbert initiates coverage on Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy rating and announces Price Target of $15.

Initiation

COYA

D. Boral Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $15

Contracts

AIRI

Air Industries announced that it has secured a follow-on contract valued at approximately $4.0M for arresting gear components to be used on the F-35 Lightning II fighter aircraft

Needham analyst Quinn Bolton maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and raises the price target from $95 to $120.

Needham Maintains Buy on Marvell Tech, Raises Price Target to $120

MGRX

Mangoceutical Announced That It Has Launched An Investigation Into Potential Stock Manipulation Related To And Following Its Recent Reverse Stock Split, Which Was Effective As Of October 16, 2024

The trial sites include esteemed institutions across the Northeast of the United States.
Additional trial sites include:
<ul>
<li>Yale University</li>
<li>Johns Hopkins University</li>
<li>Cornell University</li>
<li>University at Buffalo (SUNY)</li>
<li>University of Massachusetts (UMass)</li>
<li>Thomas Jefferson University</li>
</ul>

TLSA

Tiziana Life Sciences Broadens Phase 2 Clinical Trial For Non-Active Secondary Progressive Multiple Sclerosis To Additional U.S. Medical Institutions

STGW

Stagwell Announced The Appointment Of George Brady As CEO

Can-Fite BioPharma Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANF#NYSE">CANF</a>) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced today that a patient currently treated with Namodenoson in a compassionate use program in Can-Fite's&nbsp; Phase II Liver Cancer Study has an overall survival time of 8 years with a complete response.
The patient, who suffered from advanced liver cancer was enrolled in the former Can-Fite Phase II study, &nbsp;continue to be treated with Namodenoson, and has now an overall survival of 8 years, with &nbsp;disappearance of ascites, normal liver function, good quality of life and is defined as a long term complete response.
Can-Fite is currently enrolling patients in Israel, Europe and the US for a pivotal Phase III clinical study for patients with advanced HCC as a 2nd or 3rd line treatment and Namodenoson is administered twice daily orally. &nbsp;The study protocol has been agreed upon with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Namodenoson has Orphan Drug status with both the FDA and EMA, as well as Fast Track Status with the FDA for the treatment of HCC. A compassionate use program has been ongoing in Israel and Romania.

CANF

Can-Fite BioPharma Announced 8 Years Survival For Advanced Liver Cancer Patient Treated With Can-Fite's Namodenoson Drug

EYPT

EyePoint Pharmaceuticals Announced That The First Patient Has Been Dosed In The LUCIA Trial, The Company's Second Global Phase 3 Clinical Trial Of DURAVYU, Formerly EYP-1901, For The Treatment Of Wet Age-related Macular Degeneration

Pilbara Minerals Limited (AU:PLS) has released an update. Pilbara Minerals is poised for growth despite recent lithium price volatility, with major...

Pilbara Minerals Positions for Growth Amidst Market Challenges

Pilbara Minerals Limited (AU:PLS) has released an update. Pilbara Minerals is set to hold its 2024 Annual General Meeting on November 26, recognizi...

Pilbara Minerals Announces 2024 AGM, Honors Traditional Landowners

Pilbara Minerals Limited (AU:PLS) has released an update. Pilbara Minerals Limited successfully passed all proposed resolutions at its 2024 Annual ...

Pilbara Minerals Passes All Resolutions at AGM

Lithium Miners News For The Month Of November 2024

Pilbara Minerals Limited (AU:PLS) has released an update. UBS Group AG has become a substantial holder in Pilbara Minerals Limited, acquiring a 5.8...

UBS Group AG Acquires Stake in Pilbara Minerals

Pilbara Minerals Limited (AU:PLS) has released an update. Citigroup Global Markets has increased its stake in Pilbara Minerals Limited, now holding...

Citigroup Increases Stake in Pilbara Minerals

Pilbara Minerals Limited (AU:PLS) has released an update. Pilbara Minerals Limited has seen changes in substantial holdings as several financial in...

Pilbara Minerals Sees Shift in Substantial Holdings

Pilbara Minerals Limited (AU:PLS) has released an update. Pilbara Minerals Limited has updated its previous announcement regarding the proposed iss...

Pilbara Minerals Updates Securities Issuance Plan

Pilbara Minerals: A Deep-Value Asset

Pilbara Minerals Limited (AU:PLS) has released an update. Citigroup Global Markets has significantly reduced its stake in Pilbara Minerals, ceasing...

Comments

Pilbara Minerals

Pilbara Minerals (PILBF) Forecast

Pilbara Minerals (OTC:PILBF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga